TheranosticTrials.org

Clinical Trial · NCT01712685

Imaging Studies of Kidney Cancer Using 18F-VM4-037

Overview

Background: \- The drug 18F-VM4-037 is being tested for use in cancer imaging studies. It may help tumor tissue show up more clearly during scans. Researchers want to see how well it works for scans for people who have kidney cancer. Objectives: \- To test the safety and effectiveness of 18F-VM4-037 during imaging studies of kidney cancer. Eligibility: \- Adults at least 18 years of age with kidney cancer that will be treated with surgery. Design: * Participants will be screened with a physical exam and medical history. Blood and urine samples will be collected. * Participants will have two positron emission tomography (PET) scans of their kidneys. They will have the scans before and after receiving an injection of 18F-VM4-037. The scans will take about 2 hours to complete. * About 3 weeks after the PET scans, participants will provide tumor tissue samples from their kidneys. * This is a scanning study only. Treatment will not be provided as part of this study.

Sponsor

National Institute of Diabetes and Digestive and Kidney Diseases

Phase

Phase 2

Contacts

Adam R Metwalli, M.D. (PRINCIPAL_INVESTIGATOR)

ClinicalTrials.gov

NCT01712685

Drug / Compound

VM4-037

Isotope(s):
Target(s):
  • CAIX
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Eastern Cooperative Oncology Group (ECOG) Performance score of 0 to 2.
  • Subject must be scheduled to undergo surgery or biopsy for primary renal cell carcinoma (RCC) greater than or equal to 2.5cm in diameter or extrarenal/extrahepatic metastatic RCC lesion (greater than or equal to1cm in diameter) at the National Institutes of Health (NIH) Clinical Center based on imaging within 3 weeks.
  • Chemistry parameters: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) less than or equal to 2 times of the upper limits of normal; total bilirubin, of \< 2 times the upper limits of normal or \< 3.0 mg/dl in patients with Gilberts syndrome.
  • If female, must have a negative serum human chorionic gonadotropin (HCG) within 24 hours prior to 18F-VM4-037 injection OR be post menopausal for \> 2 years OR be surgically sterile.
  • The subject has a clinically acceptable medical history, physical examination and vital signs findings during the screening period (from within 21 days before administration of 18F-VM4-037). Components of an acceptable medical history include no active infection at the time of enrollment or within 7 days of enrollment, no prior therapy that results in immunocompromise or impaired renal function (serum creatinine within 2 weeks prior to positron emission tomography (PET) imaging less than or equal to1.8 mg/dl and epidermal growth factor receptor (eGFR) must be \> 30 ml/min/1.73m\^2) or findings indicating an inability to tolerate the requirements for the scan. Previous exposure to immunocompromising therapy does not exclude the patient; patients must have an absolute neutrophil count \> 1.5/microL within 2 weeks of PET imaging.

Exclusion

  • The site of the target lesion must not have been part of a radiation portal within 6 months of enrollment.
  • Subjects with severe claustrophobia unresponsive to oral anxiolytics.
  • Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results.
  • Subjects having received another investigational agent within 1 month before administration of 18F-VM4-037.
  • Subjects for whom participating would significantly delay the scheduled standard of care therapy.
  • Other medical conditions deemed by the principle investigator (or associates) or sponsor to make the subject ineligible for protocol procedures.
  • Female subject is pregnant or nursing